CNBC reports (video) an unusually high volume of call options in Pharmasset (VRUS +84.7%) were...

|By:, SA News Editor

CNBC reports (video) an unusually high volume of call options in Pharmasset (VRUS +84.7%) were purchased just a few days before the buyout of the company by Gilead Sciences (GILD -9.7%). Analysts say the activity may get more than a passing glance look from regulators.